Akari Therapeutics PLC Form 4 insider transactions

Director Samir Rashmikant Patel acquired 79,684,000 stock options in Akari Therapeutics Plc on October 31, 2024.

Akari Therapeutics announces the SEC's declaration of effectiveness for its Form S-4 related to the Peak Bio merger and schedules a General Meeting for shareholder approval on November 7, 2024.

Director Samir Rashmikant Patel acquires stock options in Akari Therapeutics Plc.

Director Robert B. Bazemore of Akari Therapeutics Plc was granted 5,000,000 non-qualified stock options under the company's 2023 Equity Incentive Plan.

Director Michael Grissinger of Akari Therapeutics Plc was granted 5,000,000 stock options under the company's 2023 Equity Incentive Plan.

Director Samir Rashmikant Patel acquired 91,396,000 ordinary shares in Akari Therapeutics through restricted stock units and granted a power of attorney.

Director Mohamed Wa'el Hashad of Akari Therapeutics Plc was granted 5,000,000 non-qualified stock options under the company's 2023 Equity Incentive Plan.

Donald A. Williams, a director at Akari Therapeutics Plc, was granted 5,000,000 stock options under the company's 2023 Equity Incentive Plan.

Raymond Prudo-Chlebosz, a director at Akari Therapeutics Plc, was granted 10,000,000 stock options under the company's 2023 Equity Incentive Plan.

Samir Rashmikant Patel, a director of Akari Therapeutics Plc, acquired 1,326,258,000 ordinary shares and warrants in a private placement on May 31, 2024.

Raymond Prudo-Chlebosz, a director of Akari Therapeutics Plc, acquired 1,326,258,000 ordinary shares and accompanying warrants in a private placement on May 31, 2024.

Akari Therapeutics has entered into a definitive agreement for a private placement, raising approximately $7.6 million through the sale of American Depository Shares (ADSs) and warrants.

Wendy F. DiCicco, Interim CFO of Akari Therapeutics Plc, reports acquisition of 158,473,915 ordinary shares through restricted stock units.

Akari Therapeutics announces leadership changes, including the departure of the CEO and COO, and a portfolio prioritization plan focusing on Peak Bio's ADC platform and Akari's PAS-nomacopan for Geographic Atrophy following the merger agreement with Peak Bio Inc.

Akari Therapeutics CEO Rachelle Jacques acquired 479,569,892 ordinary shares through restricted stock units on April 26, 2024.

Akari Therapeutics, Plc secures $1.615 million through a private placement of unregistered American Depository Shares (ADSs) and warrants to existing investors.

Akari Therapeutics plans to acquire Peak Bio, Inc. through a merger agreement, aiming to expand its business operations.

Akari Therapeutics and Peak Bio have entered into a definitive agreement to merge as equals in an all-stock transaction, creating an expanded pipeline with a novel antibody drug conjugate (ADC) toolkit.